Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
SANA
$4.23
$
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Beta
1.966
Average Volume
Market Cap
Last Dividend
CIK
0001770121
ISIN
US7995661045
CUSIP
799566104
CEO
Steven D. Harr
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
194
IPO Date
2021-02-04
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Sana Biotechnology to Present at March 2026 Investor Conferences | SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update. | GlobeNewsWire | 2026-02-23 16:05:00 |
| Genomics Stocks That Deserve a Place in Your Portfolio in 2026 | Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth. | Zacks Investment Research | 2026-02-20 11:51:13 |
| Sana Biotechnology: A Small, Speculative Play | Sana Biotechnology pivots to focus on its SC451 hypoimmune cell therapy for type 1 diabetes, aiming for a functional cure. Recent single-patient data validate SANA's immune-evasion technology, driving a sharp rally but underscoring early-stage risk and manufacturing challenges. With a $1B valuation and limited cash runway to YE26, SANA will likely require further dilution to fund pivotal clinical trials. | Seeking Alpha | 2026-02-13 03:24:54 |
| Sana Biotechnology, Inc. (NASDAQ:SANA) Receives Consensus Rating of “Moderate Buy” from Analysts | Sana Biotechnology, Inc. (NASDAQ: SANA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating | Defense World | 2026-02-02 04:09:00 |
| Sana Biotechnology (SANA) Is Up 5.46% in One Week: What You Should Know | Does Sana Biotechnology (SANA) have what it takes to be a top stock pick for momentum investors? Let's find out. | Zacks Investment Research | 2026-01-30 13:00:42 |
| Wall Street Analysts Think Sana (SANA) Could Surge 74.2%: Read This Before Placing a Bet | The consensus price target hints at a 74.2% upside potential for Sana (SANA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. | Zacks Investment Research | 2026-01-23 10:55:42 |
| Sana Biotechnology Stock: Promising T1D Science, But Wait For Dips | SANA's thesis rests on hypoimmune islet replacement for T1D. UP421 gives it early human validation, and SC451 is the main scalable follow-on asset. SC451's planned 2026 IND is the primary catalyst going forward. In my view, this is their make-or-break catalyst this year. A favorable Phase 1 trial could rapidly re-rate the stock even higher, especially since it targets a sizeable TAM in TD1. | Seeking Alpha | 2026-01-19 07:40:15 |
| Sana Biotechnology, Inc. (SANA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Sana Biotechnology, Inc. (SANA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript | Seeking Alpha | 2026-01-14 15:26:02 |
| Sana Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference | SEATTLE, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Wednesday, January 14, 2026. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer. | GlobeNewsWire | 2026-01-07 16:26:00 |
| Sana Biotechnology (NASDAQ:SANA) Trading 7.4% Higher Following Analyst Upgrade | Shares of Sana Biotechnology, Inc. (NASDAQ: SANA - Get Free Report) rose 7.4% on Tuesday after Bank of America raised their price target on the stock from $6.00 to $7.00. Bank of America currently has a buy rating on the stock. Sana Biotechnology traded as high as $4.46 and last traded at $4.3620. Approximately 634,615 shares | Defense World | 2026-01-07 01:28:57 |
| Three Genomics Stocks Worth Tracking This Year | Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing. | Zacks Investment Research | 2026-01-06 08:11:07 |
| Corient Private Wealth LLC Has $3.10 Million Stock Position in Sana Biotechnology, Inc. $SANA | Corient Private Wealth LLC lifted its stake in shares of Sana Biotechnology, Inc. (NASDAQ: SANA) by 264.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,136,000 shares of the company's stock after acquiring an additional 824,505 shares during the | Defense World | 2025-12-22 03:40:47 |
| Sana Biotechnology Announces Publication in Nature Biotechnology of in vivo Gene Editing of Human Hematopoietic Stem Cells in Preclinical Models Using the Fusogen Platform | Data Demonstrate Potent in vivo Gene Editing of Hematopoietic Stem Cells (HSCs) in the Bone Marrow with Systemic Delivery in Preclinical Murine Models Using Fusogen Technology | GlobeNewsWire | 2025-12-08 09:00:00 |
| Sana Biotechnology, Inc. (SANA) Presents at Evercore 8th Annual Healthcare Conference Transcript | Sana Biotechnology, Inc. (SANA) Presents at Evercore 8th Annual Healthcare Conference Transcript | Seeking Alpha | 2025-12-03 17:03:25 |
| Sana Biotechnology, Inc. (SANA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript | Sana Biotechnology, Inc. (SANA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript | Seeking Alpha | 2025-12-02 17:43:25 |
| Sana Biotechnology to Present at December 2025 Investor Conferences | SEATTLE, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer. | GlobeNewsWire | 2025-11-24 16:05:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-18 | 2026-02-18 | View Filing |
| 3 | 2026-02-18 | 2026-02-18 | View Filing |
| 8-K | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G | 2026-01-21 | 2026-01-21 | View Filing |
| 8-K | 2026-01-14 | 2026-01-14 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2026-01-06 | 2026-01-06 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-05 | 2025-12-05 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-11-06 | 2025-11-06 | View Filing |
| 4 | 2025-10-07 | 2025-10-07 | View Filing |
| 8-K | 2025-09-05 | 2025-09-05 | View Filing |
| 8-K | 2025-08-29 | 2025-08-29 | View Filing |
| 10-Q | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-08-07 | 2025-08-07 | View Filing |
| 424B5 | 2025-08-07 | 2025-08-07 | View Filing |
| 424B5 | 2025-08-06 | 2025-08-06 | View Filing |
| 8-K | 2025-08-06 | 2025-08-06 | View Filing |
| 4 | 2025-07-08 | 2025-07-08 | View Filing |
| 8-K | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 4 | 2025-06-09 | 2025-06-09 | View Filing |
| 3 | 2025-06-09 | 2025-06-09 | View Filing |
| 8-K | 2025-06-06 | 2025-06-06 | View Filing |
| 424B5 | 2025-05-08 | 2025-05-08 | View Filing |
| S-8 | 2025-05-08 | 2025-05-08 | View Filing |
| 10-Q | 2025-05-08 | 2025-05-08 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| SC 13G/A | 2025-04-25 | 2025-04-25 | View Filing |
| ARS | 2025-04-25 | 2025-04-25 | View Filing |
| DEFA14A | 2025-04-25 | 2025-04-25 | View Filing |
| DEF 14A | 2025-04-25 | 2025-04-25 | View Filing |
| 4 | 2025-04-08 | 2025-04-08 | View Filing |
| EFFECT | 2025-03-24 | 2025-03-24 | View Filing |
| POS AM | 2025-03-17 | 2025-03-17 | View Filing |
| 10-K | 2025-03-17 | 2025-03-17 | View Filing |
| 8-K | 2025-03-17 | 2025-03-17 | View Filing |
| POSASR | 2025-03-14 | 2025-03-14 | View Filing |
| 4 | 2025-03-10 | 2025-03-10 | View Filing |
| 4 | 2025-03-10 | 2025-03-10 | View Filing |
| 4 | 2025-03-10 | 2025-03-10 | View Filing |
| 4 | 2025-03-03 | 2025-03-03 | View Filing |
| 144 | 2025-02-18 | 2025-02-18 | View Filing |
| SC 13G/A | 2025-01-31 | 2025-01-31 | View Filing |
| 144 | 2025-01-16 | 2025-01-16 | View Filing |
| 8-K | 2025-01-13 | 2025-01-13 | View Filing |
| 4 | 2025-01-10 | 2025-01-10 | View Filing |
| 4 | 2025-01-07 | 2025-01-07 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 144 | 2024-12-16 | 2024-12-16 | View Filing |
| 144 | 2024-11-26 | 2024-11-26 | View Filing |
| 144 | 2024-11-25 | 2024-11-25 | View Filing |
| 3/A | 2024-11-21 | 2024-11-21 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G/A | 2024-11-12 | 2024-11-12 | View Filing |
| SC 13G | 2024-11-08 | 2024-11-08 | View Filing |
| 10-Q | 2024-11-08 | 2024-11-08 | View Filing |
| 8-K | 2024-11-08 | 2024-11-08 | View Filing |
| SC 13G/A | 2024-11-04 | 2024-11-04 | View Filing |
| SC 13G | 2024-10-22 | 2024-10-22 | View Filing |
| 144 | 2024-10-21 | 2024-10-21 | View Filing |
| 3 | 2024-10-15 | 2024-10-15 | View Filing |
| 4 | 2024-10-09 | 2024-10-09 | View Filing |
| 8-K | 2024-10-08 | 2024-10-08 | View Filing |
| 4 | 2024-09-26 | 2024-09-26 | View Filing |
| 144 | 2024-09-25 | 2024-09-25 | View Filing |
| 144 | 2024-09-24 | 2024-09-24 | View Filing |
| 8-K | 2024-09-12 | 2024-09-12 | View Filing |
| 10-Q | 2024-08-08 | 2024-08-08 | View Filing |
| 8-K | 2024-08-08 | 2024-08-08 | View Filing |
| 4/A | 2024-07-15 | 2024-07-15 | View Filing |
| 4/A | 2024-07-15 | 2024-07-15 | View Filing |
| 4/A | 2024-07-15 | 2024-07-15 | View Filing |
| 4/A | 2024-07-15 | 2024-07-15 | View Filing |
| 4/A | 2024-07-15 | 2024-07-15 | View Filing |
| 4/A | 2024-07-15 | 2024-07-15 | View Filing |
| 4/A | 2024-07-15 | 2024-07-15 | View Filing |
| 4/A | 2024-07-15 | 2024-07-15 | View Filing |
| 4/A | 2024-07-15 | 2024-07-15 | View Filing |
| 4 | 2024-07-08 | 2024-07-08 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
| 4 | 2024-06-07 | 2024-06-07 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Choppiness Index Strategy | 150.12% | 0.9 | 31 | 0.82 | 1.73 | 29.12 |
| Buy & Hold | 121.00% | 1.01 | 39 | 0.63 | 1.33 | 121 |
| Mean Variance Optimization Strategy | 121.00% | 1.01 | 39 | 0.63 | 1.33 | 0 |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | x | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xx | xxxx | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | x | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |